Medico Remedies Limited has announced a key leadership appointment, naming Ms. Vidhi Ankit Shah as the company's new Company Secretary and Compliance Officer. The appointment, effective February 18, 2026, was approved by the Board of Directors during their meeting held on the same date.

Board Meeting Outcome

The Board of Directors of Medico Remedies Limited convened on February 18, 2026, to consider and approve the appointment of Ms. Vidhi Ankit Shah as Company Secretary and Compliance Officer. The decision was made following the recommendation of the company's Nomination and Remuneration Committee, ensuring compliance with regulatory requirements under the Companies Act, 2013 and Listing Regulations.

Appointee Profile and Experience

Ms. Vidhi Ankit Shah brings substantial expertise to her new role at Medico Remedies Limited. She is an associate member of the Institute of Company Secretaries of India and possesses over 9 years of experience in managing secretarial compliances for both listed and unlisted companies. Her extensive background in corporate governance and regulatory compliance positions her well to handle the responsibilities of her new position.

Appointment Details

Regulatory Compliance

The appointment has been made in accordance with Section 203 of the Companies Act, 2013, and Regulation 6 of the Listing Regulations. The company has fulfilled all necessary regulatory disclosure requirements under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ms. Shah has formally provided her consent to act as Company Secretary and Compliance Officer, with terms and conditions to be mutually agreed upon according to the Companies Act, 2013 and Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

Company Background

Medico Remedies Limited operates as a WHO-GMP certified, ISO 9001-2015 certified pharmaceutical company and is recognized as a Government Star Export House. The company specializes in manufacturing pharmaceutical formulations and maintains its registered office in Mumbai. With this strategic appointment, the company continues to strengthen its corporate governance framework and regulatory compliance capabilities.

Medico Remedies Limited has announced its unaudited standalone financial results for the third quarter of FY26, showcasing strong operational performance across key financial metrics. The pharmaceutical formulation manufacturer reported significant growth in both revenue and profitability for the quarter ended December 31, 2025.

Financial Performance Highlights

The company's financial performance for Q3 FY26 demonstrated robust growth momentum. Revenue from operations reached ₹5,868.29 lakhs, representing a substantial 48.6% increase from ₹3,948.99 lakhs recorded in Q3 FY25. This strong revenue growth was accompanied by improved profitability, with net profit after tax reaching ₹287.23 lakhs compared to ₹261.97 lakhs in the corresponding quarter of the previous year.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, Medico Remedies maintained its growth trajectory with impressive year-over-year improvements. Total revenue from operations reached ₹14,956.96 lakhs, marking a 36.4% increase from ₹10,963.74 lakhs in the corresponding period of FY25. The company's net profit for the nine-month period stood at ₹725.86 lakhs, representing a 26.2% growth compared to ₹575.24 lakhs in the previous year.

Operational Efficiency and Cost Management

The company's operational metrics reflect effective cost management strategies. Total expenses for Q3 FY26 amounted to ₹5,552.74 lakhs compared to ₹3,741.70 lakhs in Q3 FY25. Cost of materials consumed represented the largest expense component at ₹3,618.44 lakhs, while employee benefits expense stood at ₹212.92 lakhs. The company maintained healthy profit margins with profit before tax reaching ₹383.23 lakhs for the quarter.

Geographic Revenue Distribution

Medico Remedies demonstrated strong international presence with export sales significantly outpacing domestic revenue. For Q3 FY26, sales of products outside India reached ₹5,156.03 lakhs, while domestic sales contributed ₹689.73 lakhs. This export-focused business model highlights the company's competitive positioning in international pharmaceutical markets.

Corporate Governance and Compliance

The financial results were reviewed by the audit committee and approved by the Board of Directors at their meeting held on February 12, 2026. The results have been subjected to limited review by statutory auditors Shah Shroff & Associates, who issued an unmodified report on the unaudited financial results. The company maintains its paid-up equity share capital at ₹1,659.68 lakhs with a face value of ₹2 per share.